CytomX Therapeutics (CTMX) announced the appointment of Rachael Lester as senior VP, chief business officer. In this role, Lester will lead the company’s strategy and business development functions. Lester joins CytomX with over two decades leading corporate strategy, business development and product portfolio planning across the life science and biopharmaceutical industry. Most recently, she was chief business officer at Replicate Bioscience.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- Oppenheimer positive on CytomX after Merus colon cancer data
- CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
- CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
- CytomX Therapeutics assumed with an Overweight at Barclays
- CytomX Therapeutics initiated with an Overweight at Barclays